Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.45 |
| ▸ | RXRB | P28702 | 3/20 | 0.45 |
| ▸ | RXRG | P48443 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 7/20 | 0.33 |
| ▸ | RARA | P10276 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896227 | 0.91 | POLB (0.39) | RXRARXRBRXRGPOLBRARB | |
| SCHEMBL22982796 | 0.85 | POLB (0.49) | RXRARXRBRXRGPOLBKDM4E | |
| SCHEMBL29862300 | 0.85 | POLB (0.49) | RXRARXRBRXRGPOLBKDM4E | |
| SCHEMBL2894638 | 0.81 | KDM4E (0.49) | RXRARXRBRXRGKDM4EALDH1A1 | |
| SCHEMBL17648701 | 0.78 | RXRA (0.42) | RXRARXRBRXRGKDM4EALDH1A1 | |
| SCHEMBL17649193 | 0.75 | KMT2A (0.44) | RXRARXRBRXRGPOLBKDM4E | |
| SCHEMBL2902560 | 0.72 | KDM4E (0.45) | KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL7913221 | 0.71 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL20619534 | 0.71 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30488939 | 0.71 | KDM4E (0.46) | POLBKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202228-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2202228-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
| EP-2202228-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | REN, ACE, AGT | RXRA 2549/4885RXRB 2865/4885RXRG 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.